Pharmaceutical Technology

APRIL 4, 2023

Formerly known as CTX001, exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. Vertex Pharmaceuticals chief medical officer and Global Medicines Development and Medical Affairs executive vice-president Carmen Bozic said: “The completion of our exa-cel global regulatory filings is a historic milestone. “We

Gene Therapy 246

Gene Therapy Gene Editing In-Vivo Gene 246

The Pharma Data

NOVEMBER 17, 2020

Hammond , DNP, CRNP, IVF Program Director of the America Institute of Reproductive Medicine in Birmingham, Alabama ; and. . SARASOTA, Fla. , 18, 2020 /PRNewswire/ — INVO Bioscience , Inc. Drs. and across the world. Amber R.

In-Vivo 52

In-Vivo In-Vitro Genetics Doctors 52

XTalks

FEBRUARY 10, 2023

According to a recent review published in Nature , as of April 2022 almost 1,800 active cell therapy clinical trials were listed in ClinicalTrials.gov, a 33 percent increase from 2021. The rapidly expanding landscape of cell therapy trials has put an operational strain on many clinical sites due to limited resources and infrastructure. “In

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52